CPSE:ZEAL

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Zealand Pharma A/S, a biotechnology company, engages in the discovery and development of peptide based medicines in Denmark.


Snowflake Analysis

Flawless balance sheet with limited growth.


Similar Companies

Share Price & News

How has Zealand Pharma's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ZEAL's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-2.2%

ZEAL

2.0%

DK Biotechs

-0.7%

DK Market


1 Year Return

100.6%

ZEAL

36.1%

DK Biotechs

22.3%

DK Market

Return vs Industry: ZEAL exceeded the Danish Biotechs industry which returned 35.8% over the past year.

Return vs Market: ZEAL exceeded the Danish Market which returned 23% over the past year.


Shareholder returns

ZEALIndustryMarket
7 Day-2.2%2.0%-0.7%
30 Day14.2%6.9%7.0%
90 Day2.1%12.5%4.3%
1 Year100.6%100.6%37.2%36.1%24.7%22.3%
3 Year118.0%118.0%28.6%25.9%40.5%28.8%
5 Year121.7%121.7%66.6%61.3%51.6%32.5%

Price Volatility Vs. Market

How volatile is Zealand Pharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Zealand Pharma undervalued compared to its fair value and its price relative to the market?

7.93x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ZEAL's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ZEAL's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ZEAL is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: ZEAL is unprofitable, so we can't compare its PE Ratio to the Danish market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ZEAL's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ZEAL is overvalued based on its PB Ratio (7.9x) compared to the XE Biotechs industry average (4.3x).


Next Steps

Future Growth

How is Zealand Pharma forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?

52.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ZEAL is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ZEAL is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ZEAL is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ZEAL's revenue (55.2% per year) is forecast to grow faster than the Danish market (6.5% per year).

High Growth Revenue: ZEAL's revenue (55.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ZEAL is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Zealand Pharma performed over the past 5 years?

6.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ZEAL is currently unprofitable.

Growing Profit Margin: ZEAL is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ZEAL is unprofitable, but has reduced losses over the past 5 years at a rate of 6% per year.

Accelerating Growth: Unable to compare ZEAL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ZEAL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (17.1%).


Return on Equity

High ROE: ZEAL has a negative Return on Equity (-51.3%), as it is currently unprofitable.


Next Steps

Financial Health

How is Zealand Pharma's financial position?


Financial Position Analysis

Short Term Liabilities: ZEAL's short term assets (DKK1.4B) exceed its short term liabilities (DKK187.7M).

Long Term Liabilities: ZEAL's short term assets (DKK1.4B) exceed its long term liabilities (DKK158.5M).


Debt to Equity History and Analysis

Debt Level: ZEAL is debt free.

Reducing Debt: ZEAL has no debt compared to 5 years ago when its debt to equity ratio was 148.2%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ZEAL has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: ZEAL has sufficient cash runway for 2.2 years if free cash flow continues to grow at historical rates of 14.6% each year.


Next Steps

Dividend

What is Zealand Pharma's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ZEAL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ZEAL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ZEAL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ZEAL's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ZEAL's dividend in 3 years as they are not forecast to pay a notable one for the Danish market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.2yrs

Average management tenure


CEO

Emmanuel Dulac (50yo)

1.17yrs

Tenure

ø15,914,300

Compensation

Dr. Emmanuel Dulac, PharmD, PhD, MBA, has been Chief Executive Officer at Zealand Pharma A/S since April 22, 2019 and its President since 2019. He had been Chief Commercial Officer and Senior Vice Presiden ...


CEO Compensation Analysis

Compensation vs Market: Emmanuel's total compensation ($USD2.37M) is above average for companies of similar size in the Danish market ($USD1.64M).

Compensation vs Earnings: Insufficient data to compare Emmanuel's compensation with company performance.


Leadership Team

NamePositionTenureCompensationOwnership
Emmanuel Dulac
CEO & President1.17yrsø15.91mno data
Matthew Dallas
Senior VP & CFO0.67yrø3.23mno data
Hanne Bak
Senior Project Director4.17yrsø400.00k0.026% DKK2.6m
Adam Steensberg
Executive VP of Research & Development and Chief Medical Officer1.17yrsø6.92m0.046% DKK4.5m
Ivan Møller
Senior Vice President of Technical Development & Operations2.25yrsno datano data
Rie Hansen
Interim Chief Scientific Officer & VP of Research0.83yrno datano data
Lani Morvan
Investor Relations & Communications Officerno datano datano data
Søren Keller
Head of Legal Affairs6.17yrsno datano data
Niels Mørk
Head of Bioanalysisno datano datano data
Jens Mikkelsen
Head of Molecular Pharmacologyno datano datano data

1.2yrs

Average Tenure

47yo

Average Age

Experienced Management: ZEAL's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Hanne Bak
Senior Project Director4.17yrsø400.00k0.026% DKK2.6m
Leonard Kruimer
Independent Director1.17yrsø367.00k0.011% DKK1.1m
Alain Munoz
Co-Chair of the Clinical & Scientific Advisory Board & Director8.58yrsø450.00k0.014% DKK1.4m
Alf Gunnar Nicklasson
Independent Chairman of the Board5.17yrsø850.00k0.0027% DKK264.3k
Ake Lernmark
Member of Advisory Board8.58yrsno datano data
Tyge Korsgaard
Board Observerno datano datano data
Bernard Charbonnel
Member of Advisory Board8.58yrsno datano data
Richard Pratley
Member of Advisory Board8.58yrsno datano data
Paul Dorian
Member of Advisory Board8.58yrsno datano data
Kirsten Drejer
Independent Vice Chairman1.17yrsø467.00k0.0014% DKK131.7k

8.6yrs

Average Tenure

64yo

Average Age

Experienced Board: ZEAL's board of directors are considered experienced (8.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 16.7%.


Top Shareholders

Company Information

Zealand Pharma A/S's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Zealand Pharma A/S
  • Ticker: ZEAL
  • Exchange: CPSE
  • Founded: 1997
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ø9.753b
  • Shares outstanding: 36.94m
  • Website: https://www.zealandpharma.com

Number of Employees


Location

  • Zealand Pharma A/S
  • Sydmarken 11
  • SOeborg
  • Copenhagen
  • Capital Region of Denmark
  • 2860
  • Denmark

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ZEALCPSE (OMX Nordic Exchange Copenhagen)YesOrdinary SharesDKDKKNov 2010
0NZULSE (London Stock Exchange)YesOrdinary SharesGBDKKNov 2010
22ZDB (Deutsche Boerse AG)YesOrdinary SharesDEEURNov 2010
ZLDP.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDNov 2010
ZEALCBATS-CHIXE (BATS 'Chi-X Europe')YesOrdinary SharesGBDKKNov 2010
ZEALNasdaqGS (Nasdaq Global Select)ADR EACH REP 1 ORD SHS SPONUSUSDAug 2017
22ZADB (Deutsche Boerse AG)ADR EACH REP 1 ORD SHS SPONDEEURAug 2017

Biography

Zealand Pharma A/S, a biotechnology company, engages in the discovery and development of peptide based medicines in Denmark. It has a portfolio of medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases. Its product pipeline includes glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome; dasiglucagon, a stable glucagon analog for the treatment of severe hypoglycemia in diabetes and congenital hyperinsulinism, as well as for use in dual-hormone automated pump therapy for management of type 1 diabetes; and GLP-1/glucagon dual-acting agonist for obesity/diabetes. Zealand Pharma A/S has a collaboration agreement with Sanofi-Aventis Deutschland GmbH to market lixisenatide; and a license, research and development agreement with Alexion Pharmaceuticals, Inc. to develop novel therapies to treat complement mediated diseases, as well as a collaboration agreement with Boehringer Ingelheim International GmbH to advance novel GLP-1/glucagon dual-acting peptide receptor agonists. The company was founded in 1997 and is headquartered in Copenhagen, Denmark. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/06/01 21:21
End of Day Share Price2020/05/29 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.